Pharmacyte Biotech Experiencing Marginal Success Still has Several Challenges in Coming Year: Analyst Report Issued by BrokerBank Securities, Inc.

NEW YORK, Jan. 9, 2015 /PRNewswire/ -- PharmaCyte Biotech PHCB formerly, Nuvilex Inc. NVLX as of January 8^th, 2015, based out of Silver Spring, Maryland, is a biotechnology firm leveraging its proprietary Cell-in-a-Box^® to usher in new approaches to the treatment and management of several forms of cancer. The recent name change is to highlight the shift that PharmaCyte Biotech will now be operating as a purely biotechnology firm.

PharmaCyte Biotech the owner of Cell-in-a-Box^® is using their new technology to treat as well as minimize the side effects of treatment of pancreatic cancer. The treatment has begun Phase 2b of clinical trials, and "this treatment has been shown to be safe and effective in patients with advanced inoperable pancreatic cancer" Source: Shareholders Update. PharmaCyte Biotech has also successfully been granted "orphan drug," status with the FDA, and has applications filed with their European and Australian counterpart (EMA, and the TGA).

PharmaCyte Biotech has also several other product lines including the use of their patented Cell-in-a-Box^® technology for the treatment of diabetes, as well as research into the use of cannabinoids combined with their encapsulation technology to treat serious diseases, not limited to cancer.

For a more detailed research report with analyst comments and recommendation on Pharmacyte Biotech please follow the link. There is no cost obligation required to view analyst brief:

http://bit.ly/-PHCB-AnalystReport

Copy and paste to browser may be required.

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading. 
A full disclaimer can be found by viewing the analyst report.

CFA^® and Chartered Financial Analyst^® are registered trademarks owned by CFA Institute. 
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmacyte-biotech-experiencing-marginal-success-still-has-several-challenges-in-coming-year-analyst-report-issued-by-brokerbank-securities-inc-300018318.html

SOURCE BrokerBank Securities, Inc.